Akorn, Inc. (NASDAQ: AKRX) provided the following response regarding FDA’s draft guidance on vancomycin hydrochloride (HCl) capsules. The Food and Drug Administration (FDA) has posted draft guidance for establishing bioequivalence (BE) for vancomycin HCl capsules.

More: continued here

This entry was posted on Saturday, January 3rd, 2009 at 9:01 pm and is filed under Pharma Industry. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.